Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2.

Kathrin ReetzRoberto Rodríguez-LabradaImis DoganShahram MirzazadeSandro RomanzettiJörg B SchulzEdilia M Cruz-RivasJose A Alvarez-CuestaRaul Aguilera RodríguezYanetza Gonzalez ZaldivarGeorg AuburgerLuis Velázquez-Pérez

Published in: Annals of clinical and translational neurology (2018)

Preclinical SCA2 mutation carriers exhibit brain abnormalities, which could be targeted as surrogate parameters for disease progression and in future preventive trials.

Keyphrases

white matter
resting state
cell therapy
cancer therapy
current status
early onset
stem cells
drug delivery
mesenchymal stem cells
blood brain barrier